Bottom line
PJP vs RYHIX: the short answer
PJP (Invesco Pharmaceuticals ETF) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 42% by weight.
But RYHIX is far broader, holding 135 positions to 33 for PJP, so beyond the top names it adds exposure PJP doesn't have.
PJP is cheaper at 0.58% vs 1.38% — a difference of $80 a year per $10,000 invested.
Over five years, PJP returned +9.0% a year vs +5.1% for RYHIX.
Updated Nov 19, 2026
PJP vs RYHIX side by side
| PJP | RYHIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Invesco | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.58% | 1.38% |
| Annual cost per $10k | $58 | $138 |
| 10-yr cost on $10k (prospectus) | $726 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +27.9% | +14.4% |
| 5-yr return (annualized) | +9.0% | +5.1% |
| 10-yr return (annualized) | +5.1% | +7.9% |
| Best quarter | +18.1% | +18.7% |
| Worst quarter | −14.8% | −14.4% |
| Net assets (fund) | $472.1M | $19.4M |
| Number of holdings | 33 | 135 |
| Portfolio turnover | 36% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PJP | RYHIX | Difference |
|---|---|---|---|
| 2025 | +27.9% | +14.4% | +13.5% |
| 2024 | +9.7% | +0.6% | +9.1% |
| 2023 | −2.2% | +5.8% | −8.1% |
| 2022 | −2.0% | −11.6% | +9.6% |
| 2021 | +14.5% | +19.2% | −4.8% |
| 2020 | +11.2% | +18.9% | −7.8% |
| 2019 | +4.7% | +22.8% | −18.1% |
| 2018 | −1.7% | +1.6% | −3.3% |
| 2017 | +15.3% | +23.5% | −8.2% |
| 2016 | −19.3% | −9.4% | −9.9% |
Source: Fund prospectus bar charts
Holdings overlap
10 of PJP's top 25 holdings also appear in RYHIX's top 25.
| Holding | PJP | RYHIX |
|---|---|---|
| Abbott Laboratories | 5.67% | 1.42% |
| AbbVie Inc. | 5.48% | 2.52% |
| Amgen Inc. | 5.33% | 1.56% |
| Johnson & Johnson | 5.18% | 2.88% |
| Merck & Co., Inc. | 5.06% | 2.04% |
| Eli Lilly and Co. | 5.02% | 3.63% |
| Gilead Sciences, Inc. | 4.53% | 1.39% |
| Pfizer Inc. | 4.50% | 1.25% |
| Regeneron Pharmaceuticals, Inc. | 3.14% | 0.90% |
| Bristol-Myers Squibb Co. | 2.94% | 1.22% |
Source: SEC Form N-PORT
PJP top 10
- Invesco Private Prime Fund — 7.93%
- Abbott Laboratories — 5.67%
- AbbVie Inc. — 5.48%
- Amgen Inc. — 5.33%
- Johnson & Johnson — 5.18%
- Merck & Co., Inc. — 5.06%
- Eli Lilly and Co. — 5.02%
- Corcept Therapeutics Inc. — 4.96%
- Gilead Sciences, Inc. — 4.53%
- Pfizer Inc. — 4.50%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between PJP and RYHIX?
Which is cheaper, PJP or RYHIX?
Should I own both PJP and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.